Novo Nordisk reports semaglutide cuts BMI in children 6‑12 in phase‑3 STEP Young trial

Novo Nordisk released data from the phase‑3 STEP Young trial showing that once‑weekly semaglutide reduced body‑mass index in children aged 6 to under 12. After 68 weeks, mean BMI fell 13.5% with semaglutide versus a 2.7% increase with placebo, and 79% of treated children achieved a BMI reduction compared with 23% on placebo. The study enrolled 167 participants across 48 sites and included lifestyle counseling. Safety findings noted high rates of mild‑to‑moderate gastrointestinal events but no new safety concerns for growth.

The results suggest semaglutide could become the first GLP‑1 obesity therapy for this age group, potentially expanding Novo Nordisk's market beyond adolescents. Investors should watch for regulatory filings, as approval would add a new pediatric indication and increase future sales.

  • 1The trial randomly assigned 167 children 2:1 to semaglutide (n=112) or placebo (n=55).
  • 2Mean BMI changed by –13.5% with semaglutide versus +2.7% with placebo at week 68 (between‑group difference –16.2 percentage points; 95% CI –19.4 to –12.9; P <.001).
  • 3A reduction in BMI category occurred in 79% of children receiving semaglutide versus 23% receiving placebo at week 68.
  • 4BMI fell below the obesity threshold in 38% of semaglutide‑treated children versus 2% of placebo recipients.
  • 5Adverse events were reported in 96% of semaglutide patients and 93% of placebo patients; the most common were gastrointestinal events (vomiting 70% vs 29%).

Sources